| 产品编号 | bs-6417R-PE-Cy7 |
| 英文名称 | Anti-phospho-PI3 Kinase p110 beta(Ser1070)/PE-Cy7 |
| 中文名称 | PE-Cy7标记的磷酸化磷脂酰肌醇激酶（PI3Kβ）抗体 |
| 别 名 | p-PI3Kβ(Ser1070); PI 3-kinase C2β; p110 BETA; p110Beta; Phosphatidylinositol 3 kinase catalytic beta polypeptide; Phosphatidylinositol 4 5 bisphosphate 3 kinase 110 kDa catalytic subunit beta; Phosphatidylinositol 4 5 bisphosphate 3 kinase catalytic subunit beta isoform; Phosphatidylinositol-4; Phosphoinositide 3 kinase catalytic beta polypeptide; PI3 kinase p110 subunit beta; PI3-kinase subunit beta; PI3K; PI3K beta; PI3K-beta; PI3Kbeta; PI3KCB; PIK3C1; Pik3cb; PK3CB_HUMAN; PtdIns 3 kinase p110; PtdIns-3-kinase subunit beta; PtdIns-3-kinase subunit p110-beta; 5-bisphosphate 3-kinase 110 kDa catalytic subunit beta; 5-bisphosphate 3-kinase catalytic subunit beta isoform. |
| 规格价格 | 100ul/2980元 购买 大包装/询价 |
| 说 明 书 | 100ul |
| 产品类型 | 磷酸化抗体 |
| 研究领域 | 肿瘤 细胞生物 免疫学 信号转导 细胞周期蛋白 激酶和磷酸酶 |
| 抗体来源 | Rabbit |
| 克隆类型 | Polyclonal |
| 交叉反应 | Human, Mouse, (predicted: Rat, Chicken, Dog, Pig, Cow, Horse, Guinea Pig, ) |
| 产品应用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 110-123kDa |
| 性 状 | Lyophilized or Liquid |
| 浓 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human PI3 Kinase p110 beta around the phosphorylation site of Ser1070 |
| 亚 型 | IgG |
| 纯化方法 | affinity purified by Protein A |
| 储 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存条件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 产品介绍 |
background: Phosphoinositide 3-kinases (PI 3-Ks) phosphorylate the 3’- OH position of the inositol ring of inositol lipids. They act as participants in signaling pathways that regulate cell growth by virtue of their activation in response to various mitogenic stimuli. PI 3-Ks are composed of a catalytic subunit, such as PI 3-kinase C2∫ (PIK3CB) and an adaptor subunit. PI 3-kinase C2∫ , also known as p110-∫, is a 1,070 amino acid protein that shares 42% identity with p110 of cow origin. It is expressed in several human and rodent cell lines. Studies predict that PI 3-kinase C2∫ has a role in modulating the formation and stability of å2B (ITGA2B)/∫3 (ITGB3) Integrin adhesion bonds, which are essential in shear force-induced platelet activation. Phosphorylates PtdIns, PtdIns4P and PtdIns(4,5)P2 with a preference for PtdIns(4,5)P2. Subunit: Heterodimer of a catalytic subunit PIK3CB and a p85 regulatory subunit (PIK3R1, PIK3R2 or PIK3R3). Interaction with PIK3R2 is required for nuclear localization and nuclear export. Part of a complex with PIK3R1 and PTEN. Binding to PTEN may antagonize the lipid kinase activity under normal growth conditions. Part of a complex involved in autophagosome formation composed of PIK3C3 and PIK3R4 (By similarity). Interacts with BECN1, ATG14 and RAB5A. Subcellular Location: Cytoplasm. Nucleus. Note=Interaction with PIK3R2 is required for nuclear localization and export. Tissue Specificity: Expressed ubiquitously. Similarity: Belongs to the PI3/PI4-kinase family. Contains 1 C2 PI3K-type domain. Contains 1 PI3K-ABD domain. Contains 1 PI3K-RBD domain. Contains 1 PI3K/PI4K domain. Contains 1 PIK helical domain. Database links: Entrez Gene: 5291 Human Entrez Gene: 74769 Mouse Omim: 602925 Human SwissProt: P42338 Human SwissProt: Q24JU2 Human SwissProt: Q3U4Q1 Mouse SwissProt: Q8BTI9 Mouse Unigene: 239818 Human Unigene: 213128 Mouse Unigene: 44268 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗体溶解方法 | |
| 2、抗体修复方式 | |
| 3、常用试剂的配制 | |
| 4、免疫组化操作步骤 | |
| 5、免疫组化问题解答 | |
| 6、Western Blotting 操作步骤 | |
| 7、Western Blotting 问题解答 | |
| 8、关于肽链的设计 | |
| 9、多肽的溶解与保存 | |
| 10、酶标抗体效价测定程序 | |
